PMS2 and neoplasm: Loss-of-function mutation of MLH1, accompanied MLH1 and PMS2 loss as well as high TMB are likely to be related to therapy-induced hypermutation in this case, since both MLH1 and PMS2 expressions were intact in the primary tumor sample38.